tlk286
Small moleculeexperimental
Clinical trial activity
15 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
15
Phase 3
4
Phase 4
0
Earliest trial started May 1, 2001 (NCT00022347)
Timeline
Indications
Mechanism of action
- DNADISRUPTING AGENT
DNA disrupting agent
Alkylating agent
- Glutathione reductaseSUBSTRATE
GSR substrate
Chemistry & pharmacology
Loading structure…
SMILES
N[C@@H](CCC(=O)N[C@@H](CS(=O)(=O)CCOP(=O)(N(CCCl)CCCl)N(CCCl)CCCl)C(=O)N[C@@H](C(=O)O)c1ccccc1)C(=O)O- Mol. weight
- 787.48 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL2111086 ↗
- ChEMBLCHEMBL2107319 ↗
Also known as
- canfosfamide
- canfosfamide
- canfosfamide
- canfosfamide
- canfosfamide
- canfosfamide
- canfosfamide hcl
- canfosfamide hcl
- canfosfamide hcl
- canfosfamide hcl
- canfosfamide hydrochloride
- canfosfamide hydrochloride
- canfosfamide hydrochloride
- canfosfamide hydrochloride
- canfosfamide hydrochloride
- canfosfamide hydrochloride
- gamma-glutamyl-alpha-amino-beta-(2-ethyl-n,n,n',n'-tetrakis(2-chloroethyl)phosphorodiamidate)sulfonylpropionyl-(r)-(-) phenylglycine
- n-(3-((2-((bis(bis(2-chloroethyl)amino)phosphinyl)oxy)ethyl)sulfonyl)-n-glutamyl-alanyl)-2-phenyl-glycine
- telcyta
- telcyta
- telcyta
- telcyta
- ter286
- ter286
- ter286
- ter286
- ter 286
- ter-286
- tlk286
- tlk286
- tlk286
- tlk286
- tlk286
- tlk 286
- tlk-286
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01148108 | Phase 2 | Jun 1, 2010 | Rutgers University, Telik |
| NCT00350948 | Phase 3 | May 1, 2006 | Telik |
| NCT00102973 | Phase 3 | Dec 1, 2004 | Telik |
| NCT00088556 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2004 | Telik |
| NCT00080340 | Phase 3 | Mar 26, 2004 | Telik |
| NCT00077883 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2004 | Telik |
| NCT00057720 | Phase 3 | Jun 1, 2003 | Telik |
| NCT00052065 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2003 | Telik |
| NCT00051948 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2003 | Telik |
| NCT00047801 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2002 | Telik |
| NCT00040638 | Phase 2 | Jul 1, 2002 | Telik |
| NCT00035841 | Phase 2 | Apr 1, 2002 | Telik |
| NCT00036920 | Phase 2 | Jan 1, 2002 | Cornell University, National Cancer Institute (NCI) |
| NCT00038428 | Phase 2 | Jun 1, 2001 | Telik |
| NCT00022347 | Phase 2 | May 1, 2001 | Cornell University, National Cancer Institute (NCI) |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Telik | For profit | 13 | 13 | 2 | 2001 |
| Cornell University | Academic/Hospital | 2 | 2 | 1 | 2001 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 2001 |
| Rutgers University | Academic/Hospital | 1 | 0 | 1 | 2010 |
4 organizations
Page 1 / 1